Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients?

Pancreas

Volumn 40, Issue 8, 2011, Pages 1215-1219

  Park, Kee Tae ^a   Kang, Dae Hwan ^a,b   Choi, Cheol Woong ^a   Cho, Mong ^a   Park, Su Bum ^a   Kim, Hyung Wook ^a   Kim, Dong Uk ^a   Chung, Chung Wook ^a   Yoon, Ki Tae ^a  

^a Pusan National University School of Medicine   (South Korea)

^b Pusan National University Yangsan Hospital   (South Korea)

Author keywords

acute pancreatitis; nafamostat mesilate; post ERCP pancreatitis

Indexed keywords

NAFAMSTAT MESILATE;

ACUTE PANCREATITIS; ADULT; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERAMYLASEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ACUTE DISEASE; AGED; AMYLASES; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GUANIDINES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PANCREATITIS; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 80054853852     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31822116d5     Document Type: Conference Paper

References (31)

1. Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: A comprehensive review. Gastrointest Endosc. 2004;59:845-864.
2. Andriulli A, Loperfido S, Napolitano G, et al. Incidence rates of post-ERCP complications: A systematic survey of prospective studies. Am J Gastroenterol. 2007;102:1781-1788.
3. Pezzilli R, Romboli E, Campana D, et al. Mechanisms involved in the onset of post-ERCP pancreatitis. JOP. 2002;3:162-168.
4. Keck T, Balcom JH, Antoniu BA, et al. Regional effects of nafamostat, a novel potent protease and complement inhibitor, on severe necrotizing pancreatitis. Surgery. 2001;130:175-181.
5. Choi CW, Kang DH, Kim GH, et al. Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis. Gastrointest Endosc. 2009;69:e11Ye18.
6. Iwaki M, Ino Y, Motoyoshi A, et al. Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats. Jpn J Pharmacol. 1986;41:155-162.
7. Singh P, Das A, Isenberg G, et al. Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials. Gastrointest Endosc. 2004;60: 544-550.
8. Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP: A prospective multicenter study. Am J Gastroenterol. 2001;96:417-423.
9. Saluja AK, Steer MLP. Pathophysiology of pancreatitis. Role of cytokines and other mediators of inflammation. Digestion. 1999;60(suppl 1):27-33.
10. Andriulli A, Leandro G, Federici T, et al. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: An updated meta-analysis. Gastrointest Endosc. 2007;65: 624-632.
11. Lee KT, Lee DH, Yoo BM. The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis: A randomized, multicenter controlled trial. Pancreas. 2008;37:445-448.
12. Poon RT, Yeung C, Lo CM, et al. Prophylactic effect of somatostatin on post-ERCP pancreatitis: A randomized controlled trial. Gastrointest Endosc. 1999;49:593-598.
13. Li ZS, Pan X, Zhang WJ, et al. Effect of octreotide administration in the prophylaxis of post-ERCP pancreatitis and hyperamylasemia: A multicenter, placebo-controlled, randomized clinical trial. Am J Gastroenterol. 2007;102:46-51.
14. Manolakopoulos S, Avgerinos A, Vlachogiannakos J, et al. Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: A multicenter randomized controlled trial. Gastrointest Endosc. 2002;55:470-475.
15. Zheng M, Bai J, Yuan B, et al. Meta-analysis of prophylactic corticosteroid use in post-ERCP pancreatitis. BMC Gastroenterol. 2008;8:6.
16. Cheng CL, Sherman S, Watkins JL, et al. Risk factors for post-ERCP pancreatitis: A prospective multicenter study. Am J Gastroenterol. 2006;101:139-147.
17. Elmunzer BJ, Waljee AK, Elta GH, et al. A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut. 2008; 57:1262-1267.
18. Sotoudehmanesh R, Khatibian M, Kolahdoozan S, et al. Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP. Am J Gastroenterol. 2007;102:978-983.
19. Romagnuolo J, Hilsden R, Sandha GS, et al. Allopurinol to prevent pancreatitis after endoscopic retrograde cholangiopancreatography: A randomized placebo-controlled trial. Clin Gastroenterol Hepatol. 2008;6:465-471; quiz 371.
20. Katsinelos P, Kountouras J, Chatzis J, et al. High-dose allopurinol for prevention of post-ERCP pancreatitis: A prospective randomized double-blind controlled trial. Gastrointest Endosc. 2005;61:407-415.
21. Dumot JA, Conwell DL, Zuccaro G Jr, et al. A randomized, double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis. Am J Gastroenterol. 2001;96:2098-2102.
22. Deviere J, Le Moine O, Van Laethem JL, et al. Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology. 2001;120:498-505.
23. Barkay O, Niv E, Santo E, et al. Low-dose heparin for the prevention of post-ERCP pancreatitis: A randomized placebo-controlled trial. Surg Endosc. 2008;22:1971-1976.
24. Rabenstein T, Fischer B, Wiessner V, et al. Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis. Gastrointest Endosc. 2004;59:606-613.
25. Andriulli A, Clemente R, Solmi L, et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: A multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc. 2002;56:488-495.
26. Manes G, Ardizzone S, Lombardi G, et al. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: A randomized, controlled, multicenter study. Gastrointest Endosc. 2007;65:982-987.
27. Cavallini G, Tittobello A, Frulloni L, et al. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopyYItalian Group. N Engl J Med. 1996;335:919-923.
28. Masci E, Cavallini G, Mariani A, et al. Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis. Am J Gastroenterol. 2003;98:2182-2186.
29. Zheng M, Chen Y, Yang X, et al. Gabexate in the prophylaxis of post-ERCP pancreatitis: A meta-analysis of randomized controlled trials. BMC Gastroenterol. 2007;7:6.
30. Yoshikawa T, Murakami M, Furukawa Y, et al. Effects of FUT-175, a new synthetic protease inhibitor on endotoxin-induced disseminated intravascular coagulation in rats. Haemostasis. 1983;13:374-378.
31. Mori S, Itoh Y, Shinohata R, et al. Nafamostat mesilate is an extremely potent inhibitor of human tryptase. J Pharmacol Sci. 2003;92:420-423.